Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Global intracellular CaT and sarcomere shortening in placebo- and rycal S36–treated CMs.
  • Fig. S2. Trans-stenotic systolic pressure gradient measurement after TAC.
  • Fig. S3. SR Ca2+ release events in ventricular CMs at 3 weeks after TAC.
  • Fig. S4. Representative traces of intracellular Ca2+ recordings illustrating measurement of total SR Ca2+ leak in CMs isolated from placebo- and rycal S36–treated mice at 3 weeks after TAC.
  • Fig. S5. Effect of threefold higher dose of rycal S36 (≈4 μM) on SR Ca2+ leak and myocardial remodeling at 3 weeks after TAC.
  • Fig. S6. Comparable perivascular fibrosis in placebo- and rycal S36–TAC mice.
  • Fig. S7. Unaltered intracellular Ca2+ homeostasis in placebo- and rycal S36–treated mice at 3 weeks after TAC.
  • Fig. S8. Western blot analyses of Ca2+ regulatory proteins at 9 weeks after TAC.
  • Fig. S9. Patch-clamp and telemetric analyses of the TAC-operated mice.
  • Fig. S10. Rycal S36 rescues SR Ca2+ leak in CPVT-E4076K CMs.
  • Fig. S11. Electrophysiological analyses of the WT and Ryr2RS/WT mice at 3 weeks after shunt.
  • Fig. S12. Increased SR Ca2+ leak in Ryr2RS/WT mice at 3 weeks after shunt.
  • Fig. S13. Increased SR Ca2+ leak but comparable survival and functional deficit in Ryr2RS/WT versus WT mice after shunt.
  • Fig. S14. Pathological myocardial remodeling is not different in WT and Ryr2RS/WT animals at 9 weeks after shunt.
  • Fig. S15. Western blot analyses of Ca2+ regulatory proteins in WT/WT and Ryr2RS/WT (RS/WT) mice at 9 weeks after shunt.
  • Table S1. Echocardiographic parameters of placebo- and rycal S36–treated mice at 3 and 9 weeks after TAC.
  • Table S2. Echocardiographic parameters at 3 weeks after surgery of mice treated with a threefold higher dose of rycal S36.
  • Table S3. Echocardiographic parameters of placebo- and dantrolene-treated mice at 7 weeks after TAC.
  • Table S4. Raw APD time values at 9 weeks after surgery.
  • Table S5. ECG parameters at 9 weeks after surgery.
  • Table S6. Echocardiographic parameters of placebo- and rycal S36–treated mice at 3 and 6 weeks after MI.
  • Table S7. Clinical data of explanted human hearts.
  • Table S8. Echocardiographic parameters of WT and Ryr2RS/WT mice at 20 weeks after shunt.
  • References (5357)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: